TABLE 2.
Univariate analysis of risk factors associated with overall survival.
| Characteristic | HR | 95% CI | p value | |
|---|---|---|---|---|
| Gender | F/M | 0.883 | 0.618–1.261 | 0.493 |
| Age (years) | >55/≤55 | 0.813 | 0.636–1.040 | 0.099 |
| ECOG | 1/0 | 0.370 | 0.052–2.655 | 0.323 |
| Etiology | HBV/others | 0.917 | 0.652–1.290 | 0.619 |
| Cirrhosis | Yes/no | 0.928 | 0.713–1.209 | 0.582 |
| Tumor size (cm) | >5/≤5 | 1.750 | 1.362–2.249 | <0.001 |
| No. of nodules | ≥3/<3 | 1.227 | 0.961–1.567 | 0.101 |
| PVTT | Yes/no | 1.864 | 1.429–2.432 | <0.001 |
| Hepatic vein invasion | Yes/no | 1.283 | 0.868–1.895 | 0.211 |
| Child-Pugh class | B/A | 1.597 | 0.593–4.297 | 0.354 |
| ALBI grade | 3/2/1 | 1.389 | 1.095–1.762 | 0.007 |
| Tumor distribution | Bilobar/unilobar | 1.146 | 0.887–1.479 | 0.297 |
| Extrahepatic spread | Yes/no | 2.461 | 1.673–3.621 | <0.001 |
| AFP (ng/dl) | >200/≤200 | 1.418 | 1.107–1.817 | 0.006 |
| AST (U/L) | >40/≤40 | 1.479 | 1.155–1.894 | 0.002 |
| ALT (U/L) | >40/≤40 | 1.129 | 0.883–1.443 | 0.334 |
| Albumin (g/L) | >35/≤35 | 0.698 | 0.526–0.926 | 0.013 |
| TBIL (umol/L) | >17.1/≤17.1 | 1.089 | 0.754–1.573 | 0.648 |
| NLR | ≥2.42/<2.42 | 1.647 | 1.287–2.109 | <0.001 |
| PLR | ≥100/<100 | 1.576 | 1.231–2.018 | <0.001 |
| AST/ALT | >1.18/≤1.18 | 1.328 | 1.037–1.701 | 0.025 |
AFP, alpha-fetoprotein; ALBI, albumin-bilirubin; ALT, alanine transaminase; AST, aspartate transaminase; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PVTT, portal vein tumor thrombus; TBIL, total bilirubin; HR, hazard ratio; CI, confidence interval.